While its adoption trails behind earlier SGLT2 inhibitors due to lesser real-world familiarity and GI tolerability concerns, sotagliflozin offers a distinct mechanistic profile—particularly beneficial in patients with prominent postprandial hyperglycemia or combined cardiorenal disease. The gene discussed is SLC5A2; the disease is Hyperglycemia.